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n response to retinoic acid, embryonic stem and carcinoma
cells undergo differentiation to embryonic primitive
endoderm cells, accompanied by a reduction in cell
proliferation. Differentiation does not reduce the activation
of cellular MAPK/Erk, but does uncouple mitogen-activated
protein kinase (MAPK) activation from phosphorylation/
activation of Elk-1 and results in inhibition of c-Fos expression,
whereas phosphorylation of the cytoplasmic substrate
p90RSK remains unaltered. Cell fractionation and confocal
immunoﬂuorescence microscopy demonstrated that activated
MAPK is restricted to the cytoplasmic compartment after
I
 
differentiation. An intact actin and microtubule cytoskeleton
appears to be required for the restriction of MAPK nuclear
entry induced by retinoic acid treatment because the cyto-
skeletal disrupting agents nocodazole, colchicine, and
cytochalasin D are able to revert the suppression of c-Fos
expression. Thus, suppression of cell proliferation after
retinoic acid–induced endoderm differentiation of embryonic
stem and carcinoma cells is achieved by restricting nuclear
entry of activated MAPK, and an intact cytoskeleton is
required for the restraint.
 
Introduction
 
In vitro, multipotent F9 embryonic carcinoma (EC) and
pluripotent embryonic stem (ES) cells undergo differentiation
in response to treatment with retinoic acid (RA) to primitive
endoderm-like cells (Sherman and Miller, 1978). The prim-
itive endoderm lineage is an epithelial cell type present in the
blastocyst stage of the early mouse embryo that gives rise to
the extraembryonic tissues (Sherman and Miller, 1978;
Robertson, 1987). RA-differentiated F9 and ES cells express
endoderm markers GATA-4 (Arceci et al., 1993), GATA-6
(Morrisey et al., 1998; Koutsourakis et al., 1999), Disabled-2
(Cho et al., 1999; Morrisey et al., 2000; Smith et al.,
2001b), tissue plasminogen activator, and components of the
basement membrane, collagen type IV and laminin (Vasios et
 
al., 1989; Faria et al., 1999). The cellular changes that ac-
company EC and ES cell differentiation closely follow those
that occur in the early embryo, and F9 cells are frequently used
to study the effects of RA on differentiation, proliferation,
and embryonic development (Boylan and Gudas, 1991).
In addition to changes in cellular morphology and gene
expression, the differentiated F9 cells exhibit a suppressed or
impaired response to growth factors or serum and a reduced
growth rate (Sherman and Miller, 1978; Faria et al., 1999).
In many mammalian cell types, the Ras–MAPK cascade is the
principal mitogenic signaling pathway and MAPK activation
is essential for cell growth (Brunet et al., 1999; Hochholdinger
et al., 1999; Kim-Kaneyama et al., 2000). The Ras–MAPK
signaling pathway mediates the cellular response to multiple
growth factor receptor tyrosine kinases, and the transmittance
of the signal from the extracellular receptor at the cell surface
 
to changes in gene expression has been well described (Robinson
and Cobb, 1997; Chang and Karin, 2001). Specifically,
a linear pathway from receptor tyrosine kinase–Ras–Raf–
MAPK kinase (MEK) results in phosphorylation and activation
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of MAPK or extracellular signal–regulated kinase (ERK),
p44/42 MAPK or ERK1 and 2, respectively, by MEK and
subsequent phosphorylation/activation of, among several
targets, the transcription factor Elk-1. Elk-1 is responsible
for transcriptional activation of the immediate early gene
 
c-fos
 
 through binding to the Ets/SRE element in the 
 
c-fos
 
promoter (Gille et al., 1992; Marais et al., 1993; Yang et al.,
1999). c-Fos interacts with the transcription factor Jun to
form the AP-1 complex, which mediates the biological re-
sponse, including cell cycle progression in serum-starved
growth-arrested cells (Field et al., 1992). Moreover, c-Fos
expression contributes to and is required for the malignant
growth of solid tumors (Angel and Karin, 1991; Saez et al.,
1995; Arteaga and Holt, 1996), and down-regulation of
c-Fos expression interferes with the growth of tumor cells in
vitro (Arteaga and Holt, 1996). Thus, c-Fos is likely a site of
regulation in cell growth control (Altin et al., 1992; Brown
et al., 1998; Vanhoutte et al., 2001). In F9 cells treated for
4 d with RA to induce endodermal differentiation, serum
causes a rapid and significant activation of MAPK; however,
c-Fos expression is consistently suppressed (Smith et al.,
2001a,b). This uncoupling of MAPK activation from c-Fos
expression occurs at the step of Elk-1 phosphorylation/acti-
vation by MAPK.
Both the duration and the localization of the Ras/MAPK
signal are normally regulated during proliferation and differ-
entiation of many cell types (Pouyssegur et al., 2002). Dual
phosphorylation of MAPK on tyrosine and threonine by
MEK occurs in the cytoplasm, and several nonspecific phos-
phoserine/phosphothreonine- and phosphotyrosine-specific
phosphatases and a MAPK-specific phosphatase (MKP3)
have been reported to dephosphorylate and inactivate p44/
p42 MAPK/Erk (Camps et al., 1998; Keyse, 2000), effec-
tively terminating the signal. Activated MAPK must translo-
cate into the nucleus to phosphorylate Elk-1 and other nu-
clear targets. The MAPK-specific phosphatases MKP1 and
MKP2, which are neosynthesized in response to MAPK
pathway stimulation (Volmat et al., 2001), are also stabilized
by MAPK-dependent phosphorylation (Brondello et al.,
1999) and reside in the nucleus (Brondello et al., 1995),
where they may also rapidly terminate MAPK activity acting
in a feedback loop. Presumably, under resting conditions,
nonphosphorylated MAPK is complexed with MEK in the
cytoplasm, and upon phosphorylation disassociates from
MEK and either freely diffuses as a monomer through nu-
clear pores (Adachi et al., 1999), homodimerizes and en-
ters the nucleus via a carrier-free/nuclear pore–independent
mechanism (Khokhlatchev et al., 1998), or interacts with
the nuclear pore complex for entry (Matsubayashi et al.,
2001; Whitehurst et al., 2002). In the nucleus, the signal
must be terminated by dephosphorylation and MAPK relo-
cated to the cytoplasm via a MEK-dependent active trans-
port (Adachi et al., 2000).
To understand how endoderm differentiation of F9 EC
cells altered growth factor–stimulated c-Fos expression,
we focused on active MAPK and its sustained nucleocyto-
plasmic localization. Here, we report that in differentiated
F9 EC cells, and to a similar extent in differentiated
mouse ES cells, MAPK does not enter the nucleus upon
serum stimulation but remains activated in the cytoplasm.
Thus, in differentiated cells, the transcriptional-depen-
dent (nuclear) and -independent (cytoplasmic) MAPK ac-
tivation are uncoupled by the restriction of MAPK nu-
clear entry.
 
Results
 
RA-induced endodermal differentiation of ES and EC 
cells results in uncoupling of MAPK activation and 
c-Fos expression
 
The F9 EC cells originally derived from a spontaneous
mouse testicular teratocarcinoma typically remain multi-
potent and undifferentiated until induced by RA and have
served as a useful model for studying endoderm differentia-
tion of ES cells (O’Shea, 2001). RA-induced F9 differenti-
ation is accompanied by growth suppression, and the F9
cells have also been used as a common model to study the
antiproliferative activity of RA (Faria et al., 1999). Re-
cently, the mechanism of RA-induced growth suppression
of F9 cells was uncovered; i.e., the differentiation results
in uncoupling of MAPK activation and c-Fos expression
(Smith et al., 2001a,b). It was of interest to determine
whether or not similar regulation of the Ras–MAPK path-
Figure 1. RA induces differentiation and cell growth suppression 
similarly in ES and F9 cells. Monolayer mouse ES or F9 cells on 
gelatin-coated plates were treated with 0.1  M RA or DMSO solvent 
control for 4 d. Medium for ES cells is either with or without LIF. 
(A) ES cells were photographed. (B) ES cells cultured with or without 
RA and in the presence of LIF were analyzed by Western blot for 
Disabled-2 (Dab2), GATA-4, and Oct-3/4.  -actin was measured as 
a protein loading control. (C) Cell number was determined by MTT 
assay, measuring absorbance at 570 nm. Equal numbers (10
4) of ES 
or F9 cells were treated with or without RA and LIF for 4 d, and the 
cells were then incubated with MTT reagent for 2 h to measure 
cellular metabolism. Triplicate wells of cells in 96-well plates were 
used in each experiment, and the mean   SD is reported here. 
The experiment was repeated three times with identical results. 
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way occurs in ES cells, which also differentiate to endo-
derm cells with RA treatment (Rohwedel et al., 1999).
Upon addition of RA for 4 d, ES cells in monolayer culture
exhibit a morphological change (Fig. 1 A), and the cells are
flattened and spread out. ES cells cultured without leuko-
cyte inhibitory factor (LIF) rapidly degenerated either in
the presence or absence of RA, and cell death was abun-
dant. After RA treatment for 4 d, the endoderm markers
Disabled-2 (Fig. 1, Dab2) and GATA-4 are induced, and
the expression of the undifferentiated ES cell marker Oct-
3/4 is lost (Fig. 1 B).
Similar to F9 cells, the proliferation/growth of the ES cells
was reduced approximately twofold with RA treatment for
4 d, determined by MTT cell proliferation assay (Fig. 1 C).
In medium without LIF to suppress spontaneous differentia-
tion, the cell number was much reduced, most likely due to
cell death and suppression of growth either in the presence
or absence of RA. Also, we assessed the effect of RA differen-
tiation of ES cells on downstream targets of MAPK activa-
tion, Elk-1 phosphorylation, and c-Fos expression. Serum
stimulation resulted in a sustained, significant elevation in
phosphorylated MAPK/Erk (pErk) levels in differentiated
ES cells compared with control cells, 
 
 
 
4.5-fold higher at the
15-min time point (Fig. 2 A). Despite an increase in total
MAPK activation, c-Fos expression in differentiated cells at
90 min is slightly lower, 0.64 times that of the undifferenti-
ated cells. Thus, similar to F9 cells (Fig. 2 B), RA-induced
differentiation of ES cells causes an uncoupling of MAPK
activation from c-Fos expression and reduced cell prolifera-
tion (Fig. 2 A).
 
Endoderm differentiation differentially affects 
phosphorylation of MAPK nuclear and 
cytoplasmic substrates
 
Previously, we have determined that the dephosphorylation
of Elk-1 by an Elk-1 phosphatase is not the mechanism ac-
counting for the RA-induced uncoupling of MAPK activa-
tion to Elk-1 phosphorylation/activation and c-Fos ex-
pression (Smith et al., 2001b). To further investigate the
mechanism for MAPK–Elk-1–c-Fos regulation, we examined
additional MAPK substrates and related signaling pathways.
Consistent with previous observations (Smith et al., 2001b),
serum (FBS) stimulation resulted in phosphorylation/activa-
tion of the transcription factor Elk-1 in control or undiffer-
entiated F9 cells (Fig. 3). In differentiated F9 cells, MAPK
activation was significant, and in most experiments, phos-
phorylated MAPK is present even in nonstimulated (Fig. 3,
FBS
 
 
 
) and nonsynchronized (Fig. 3, NS) cells grown con-
tinuously in the presence of serum. However, serum stimula-
tion and MAPK activation failed to phosphorylate/activate
Elk-1 in those cells (Fig. 3). Differentiation did not alter the
response of another growth factor–responsive pathway to se-
rum stimulation because there was no significant difference
in the amount of AKT phosphorylated in undifferentiated or
differentiated F9 cells (Fig. 3). This result indicates that the
alteration in serum responsiveness is specific to the MAPK–
Elk-1–c-Fos signaling pathway. Moreover, differentiation
does not suppress pan-MAPK activity because phosphoryla-
tion of p90RSK, a cytoplasmic MAPK substrate (Form-
stecher et al., 2001), was not suppressed by RA treatment
(Fig. 3). Thus, it appears that the phosphorylation of MAPK
substrates is differentially regulated; the phosphorylation of
Figure 2. RA-induced differentiation of ES cells elevates MAPK 
activation relative to c-Fos expression. (A) Monolayer ES cells were 
treated with 0.1  M RA for 4 d, serum starved overnight, and stimulated 
the next day with 15% FBS. At indicated time points, cells were 
disrupted in NP-40 lysis buffer and equal protein was loaded for 
each sample. Activated MAPK (pErk2/1) and c-Fos were determined 
by immunoblotting of lysates of undifferentiated ( RA) and differen-
tiated ( RA) ES cells stimulated with 15% FBS for 0–90 min. The 
experiment was repeated three times with identical results. (B) Parallel 
experiments using F9 cells are shown for comparison. The results of 
the 0- and 90-min time points are shown.
Figure 3. RA-induced differentiation of F9 cells suppresses phos-
phorylation of nuclear but not cytoplasmic MAPK substrates. 
F9 cells were treated with 0.1  M RA for 4 d, serum starved overnight, 
and stimulated with or without 15% FBS for 15 min. Another set of 
cells remained nonsynchronized (NS) by culturing in the presence 
of serum at all times. Cells were disrupted in lysis buffer, and equal 
protein was loaded for each sample. The cell lysates were analyzed 
by immunoblotting for phospho-pErk2/1, -Elk-1, -p90RSK, -AKT, 
and  -actin (Actin) in undifferentiated ( RA) and differentiated 
( RA) F9 cells that had been serum starved ( FBS), serum stimulated 
( FBS), or grown continuously in the presence of serum, or non-
synchronized (NS). 
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MAPK nuclear substrate (Elk-1) is suppressed, but the phos-
phorylation of cytoplasmic substrate (p90RSK) remains ac-
tive after RA-induced differentiation.
 
MAPK nucleocytoplasmic distribution determined 
in cell fractions
 
Because phosphorylation/activation of nuclear Elk-1 depends
on the presence of MAPK in the nucleus, we examined
whether or not differentiation alters the subcellular distribu-
tion of active MAPK (pErk). We separated F9 cells into nu-
clear and cytosolic fractions by differential centrifugation and
verified the purity of the fractions by assaying for markers of
both compartments (Fig. 4 A). Determination by Western
blot of the endocytic vesicle-coating protein clathrin as a cy-
tosolic marker and the GATA-4 transcription factor as a nu-
clear marker indicates that there is no significant cross-con-
tamination between cytosolic and nuclear components in the
fractions. The same fractions were used to determine the
distribution of the phosphorylated and unphosphorylated
MAPK and Elk-1 (Fig. 4 B). In undifferentiated cells, phos-
phorylated or activated MAPK and Elk-1 are present in both
nuclear and cytosolic fractions, as shown by immunoblots of
isolated nuclear and cytoplasmic fractions of F9 cells. After
differentiation, the active pErk is abundant in the cytosolic
fraction but is greatly reduced in the nuclear fraction. Thus,
cell fractionation indicates that activated MAPK is no longer
located in the nucleus in RA-differentiated F9 cells. In undif-
ferentiated cells, total Erk level increases in the nucleus upon
serum stimulation (Fig. 4 B), indicating nuclear translocation
upon activation of the kinase. In differentiated cells, nuclear
entry of total MAPK is greatly reduced (Fig. 4 B).
The nucleocytoplasmic distribution of the total Elk-1 level
appears not to change significantly by serum stimulation or
RA-induced differentiation (Fig. 4 B). Interestingly, com-
pared with most transiently transfected cell lines, in F9 cells
as in adult rat brain (Sgambato et al., 1998), a large fraction
of Elk-1 is cytoplasmic and phosphorylated after serum addi-
tion. Although an equal amount of Elk-1 is located in the
nucleus in differentiated and undifferentiated F9 cells, the
amount of activated/phosphorylated Elk-1 located in the nu-
cleus is 5.6 times greater in undifferentiated cells (Fig. 4 B).
In another experiment, the fractionated cellular compo-
nents were further analyzed for additional proteins (Fig. 4
C). AKT is mainly cytoplasmic. The nucleocytoplasmic dis-
tribution of p90RSK phosphorylated either dually at Thr
359/Ser 363 or on Ser 380 correlates well with the distribu-
tion of phosphorylated MAPK. In undifferentiated F9 cells,
there is a small fraction of phospho-p90RSK in the nucleus,
which is absent in differentiated cells. Thus, it appears that
p90RSK has a separate larger nuclear and smaller cytoplas-
mic pool. These results can be explained by the assumption
that MAPK is no longer able to enter the nucleus to phos-
phorylate nuclear p90RSK in differentiated cells, and only
cytoplasmic p90RSK is phosphorylated.
Figure 4. Activated MAPK is localized in the cyto-
plasmic fraction of differentiated F9 cells, determined 
by fractionation. F9 cells, induced to differentiate to 
endoderm-like cells with 0.1  M RA for 4 d, were 
serum starved ( FBS), serum restimulated for 15 min 
( FBS), or maintained nonsynchronized (NS). Cells 
were fractionated to obtain nuclear and cytoplasmic 
fractions, and equal amounts of sample protein were 
separated on SDS–polyacrylamide (7.5%) gels and 
immunoblotted for (A) cytosolic (Clathrin) and nuclear 
(GATA-4) markers or (B) Elk-1, phospho-Elk-1 (P-Elk-1), 
MAPK/Erk (Erk), and phospho-MAPK/Erk (P-Erk). 
(C) The nucleocytoplasmic distribution of pErk, pAKT, 
p90RSK (S380 and T359/S363), and  -actin is shown. 
Cell fractionation experiments were done four times 
with similar conclusions. 
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MAPK nucleocytoplasmic location determined by 
immunofluorescence microscopy
 
To confirm that RA-induced differentiation alters MAPK
nucleocytoplasmic localization, we examined activated
MAPK (pErk) localization using indirect immunofluores-
cence confocal microscopy. In undifferentiated F9 cells, nu-
clear localized pErk was detectable within 5 min, reached
maximum by 15 min, and remained visible 30–60 min after
serum addition (Fig. 5). This time course closely corre-
sponds to MAPK activation in total F9 cell lysates deter-
mined by immunoblot analysis (Smith et al., 2001a,b;
Smedberg et al., 2002). In RA-treated cells, activated MAPK
could be readily detected 5 min after serum addition,
reached maximum by 15 min, and remained elevated after
3 h. However, the pattern of cellular distribution of pErk is
strikingly different between differentiated and undifferenti-
ated F9 cells. In undifferentiated cells, pErk staining exhibits
a punctate pattern throughout the cell body. In contrast, in
differentiated cells, pErk staining is exclusively in the outer
ring of the cells, and no significant pErk was detectable in
the nucleus (Fig. 5). The nuclear exclusion of the active
MAPK is best illustrated by overlapping of pErk staining
with propidium iodide (PI) to show the nucleus (Fig. 5).
For ES cells, the difference of MAPK nuclear translocation
between undifferentiated and differentiated cells is also de-
tectable by confocal immunofluorescence microscopy. As
shown in immunofluorescence staining of phospho-Erk in ES
cells (Fig. 6 A), MAPK activation occurred within 5 min of
serum addition and corresponded to nuclear-localized phos-
phorylated MAPK (pErk) in undifferentiated ES cells. The
signal diminished rapidly thereafter, and any of the low level
of pErk remaining was primarily cytoplasmic by 15–30 min.
In contrast, phospho-MAPK/pErk in RA-treated ES cells was
mainly cytoplasmic at all times after serum addition, although
the signal persisted and remained augmented after 1 h (Fig. 6
B). Thus, nuclear translocation of phosphorylated/activated
MAPK is impaired in differentiated F9 and ES cells.
 
Inhibition of nuclear export does not alter c-Fos 
expression in F9 cells
 
The above observations establish that differentiated EC and
ES cells have the ability to prevent an accumulation of acti-
vated MAPK in the nucleus despite an increased cytoplasmic
MAPK activation. It is possible that differentiation alters the
rate of export of the activated MAPK from the nucleus, such
that export is accelerated or an anchoring protein required
for p-MAPK nuclear retention is reduced, and the amount
of nuclear p-MAPK at a given time after serum stimulation
is lowered in differentiated cells. If this were the case, inhibi-
tion of export would be predicted to retain active MAPK in
the nucleus and to elevate c-Fos expression. However, when
F9 cells were treated with leptomycin B, a specific inhibitor
of nuclear export of proteins that has been shown to prevent
MAPK translocation to the cytoplasm in 
 
Xenopus laevis 
 
A6
and rat 3Y1 cells (Adachi et al., 2000), we found no in-
creases in c-Fos expression either in RA-treated or -untreated
F9 cells (Fig. 7 A) and no effect on MAPK activation. More-
over, as shown by immunofluorescence microscopy for acti-
vated MAPK/phospho-Erk (Fig. 7 B), leptomycin B did not
alter the distribution of the activated kinase in differentiated
F9 cells, p-MAPK remained cytoplasmic in the presence of
leptomycin B in RA-treated cells. Therefore, RA-induced
differentiation does not increase the rate of export of the ac-
tivated MAPK from the nucleus. Nevertheless, leptomycin B
treatment did result in the nuclear accumulation of total
MAPK in the nucleus of both differentiated and undiffer-
entiated cells (Fig. 7 C). We interpret this result to mean
that the nucleocytoplasmic trafficking of unphosphorylated
MAPK is not perturbed by RA treatment, and once export
of unphosphorylated MAPK is inhibited by leptomycin B,
total MAPK accumulates as unregulated MAPK nuclear im-
port continues. Previously, we have also ruled out that RA
increases the activity of a phosphatase (Smith et al., 2001b).
Thus, the data suggest that an increased rate of nuclear ex-
port of the activated MAPK is unlikely the affected step; in-
Figure 5. Immunofluorescence microscopic localization of activated 
MAPK in F9 cells. F9 cells in monolayer culture, with or without 
differentiation by RA for 4 d, were serum starved overnight and 
stimulated with serum. At the indicated times, cells were fixed with 
ice-cold methanol and stained with an antiactivated/phosphorylated 
p42/p44 MAPK mAb (p-Erk) and analyzed by immunofluorescence 
confocal microscopy. Control cells were treated with DMSO vehicle 
and processed identically. Control ( RA) and differentiated ( RA) 
F9 cells were serum stimulated for 0–180 min, and phospho-MAPK 
(Cy-2–labeled; green) is shown. Nuclear PI staining is overlayed 
(p-Erk/PI) with activated MAPK (pErk). The experiment was performed 
four times with similar results. 
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stead, nuclear entry of activated MAPK is suppressed after
RA-induced endoderm differentiation of ES and EC cells.
 
Disruption of the cellular cytoskeleton abolishes 
suppression of c-Fos expression in RA-differentiated 
F9 cells
 
Previous papers have reported that MAPK associates with
the microtubule network (Reska et al., 1995) and that the
cell cytoskeleton regulates adhesion-related MAPK activity
and nucleocytoplasmic localization (Aplin et al., 2001). To
determine the influence of the cell cytoskeleton on serum-
stimulated c-Fos expression and MAPK activation, F9 cells
were differentiated with RA for 4 d and preincubated for 30
min with various cytoskeleton-depolymerizing agents before
stimulating with serum for 90 min. Nocodazole (10 
 
 
 
M)
and colchicine (10 
 
 
 
M), both destabilizers of microtubules,
appeared to increase the levels of activated MAPK slightly
(2.4- and 1.5-fold, respectively). Independently of the differ-
entiation state, c-Fos expression is augmented in the pres-
ence of nocodazole or colchicine (Fig. 8 A). Similarly, inhi-
bition of actin polymerization and barbed-end filament
growth by cytochalasin D (Cooper, 1987) slightly elevated
phosphorylated MAPK (2.6-fold) and eliminated c-Fos sup-
pression by RA-induced differentiation (Fig. 8 A). Although
disruption of the microtubule and actin cytoskeleton by no-
codazole, colchicine, or cytochalasin D treatment causes ob-
servable changes in cellular morphology, most striking is
that the cells round up and shrink, the activation of MAPK
and expression of c-Fos are enhanced, and the suppression of
c-Fos expression by RA-induced differentiation is prevented.
Thus, it appears that an intact microtubule and actin cyto-
skeleton is required for restriction of MAPK nuclear entry in
differentiated F9 cells. Furthermore, we show that the cyto-
skeleton disrupting agent-stimulated activation and c-Fos
expression is MAPK dependent because the MEK inhibitor
U0126 suppressed MAPK activation and c-Fos expression in
both the absence or presence of cytochalasin D (Fig. 8 B).
 
Discussion
 
In the past 30 yr, many laboratories have investigated the
phenomenon that RA can suppress the growth of F9 cells.
The RA-induced F9 growth suppression and endoderm dif-
ferentiation has been used as a popular model to investigate
the mechanism of the antiproliferative activity of RA, yet the
cause of growth suppression has not been determined for
certain. In several of our recent investigations, we found that
upon RA-induced differentiation c-Fos expression is sup-
Figure 6. Cellular distribution of activated MAPK in ES cells determined by immunofluorescence microscopy. ES cells, induced with RA 
for 4 d, were serum starved overnight and restimulated with serum. At the indicated time points, cells were fixed with ice-cold methanol, 
stained with an antiactivated p42/p44 MAPK mAb, and analyzed by immunofluorescence confocal microscopy. Control ES cells with added 
DMSO vehicle without RA were processed identically. (A) Control ( RA) and (B) differentiated ( RA) ES cells were serum stimulated for 
0–60 min, and phospho-MAPK (Alexa 488–labeled; green) and nuclear PI (red) are shown individually and merged. The experiment was 
performed three times with similar results. 
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pressed and uncoupled from MAPK activation (Smith et al.,
2001a,b; Smedberg et al., 2002). This paper further shows
that the mechanism is the restriction of MAPK nuclear lo-
calization upon differentiation, and both ES and EC cells
behave similarly. Thus, we conclude that in RA-differenti-
ated ES and EC (F9) cells, the transcription-dependent (nu-
clear) but not the transcription-independent (cytoplasmic)
activity of MAPK is restricted, leading to growth suppres-
sion (Fig. 9).
 
Mechanism of RA-induced growth suppression of EC 
and stem cells
 
Several mechanisms have been proposed to explain the re-
duction in cell proliferation and impaired growth factor re-
sponsiveness that accompany differentiation. A reduction in
expression of the protooncogene c-myb RNA and c-Src
RNA (Lockett and Sleigh, 1987) and c-myc RNA (Sejersen
et al., 1985; Dean et al., 1986) seen during F9 endoderm
differentiation has been correlated with the reduced growth
rate. Alternatively, targeted disruption of both alleles of the
RA receptor RAR
 
 
 
2 
 
results in loss of RA-associated growth
arrest, suggesting that RAR
 
 
 
2
 
 is essential for reduced cell
proliferation rate (Faria et al., 1999). This result has been re-
lated to a reduction in maximal expression of RA-responsive
genes at a later time after RA treatment (
 
 
 
24 h) or a re-
duced differentiation response. Genetic deletion of the reti-
noic X receptor 
 
 
 
 (RXR
 
 
 
) in F9 cells also abolishes en-
dodermal differentiation and impairs the antiproliferative
response to RA and down-regulation of p21
 
CIP
 
 and p27
 
KIP
 
,
cyclin-dependent kinase inhibitors that function in the con-
trol of cell cycle progression (Bastien et al., 2002). Alter-
ations in the cell cycle have also been thought to be responsi-
ble for the reduced proliferation rate, where differentiation
appears to lengthen the G
 
1
 
 phase and decrease the S phase
components (Kurki et al., 1989). These findings are not
necessarily mutually exclusive. This work finds that RA-
induced differentiation uncouples MAPK activation from
c-Fos expression by suppressing serum-stimulated nuclear
translocation of activated MAPK. Because proliferation is
MAPK dependent and c-Fos influences cell cycle progres-
sion and cyclin D1 expression after serum-induced reentry
into the cell cycle (Brown et al., 1998), cell growth rate is
decreased. It should be noted that a reduced c-Fos expres-
sion coincides with the fact that cell cycle transit is length-
ened (Kurki et al., 1989). We conclude that the restriction
of nuclear entry of activated MAPK is the causative mecha-
nism of the growth suppression of F9 cells treated with RA.
In differentiated F9 cells, Ras/MAPK activation is enhanced;
Figure 7. Leptomycin B does not reverse the inhibition of c-Fos 
expression or affect MAPK localization in RA-differentiated F9 
cells. (A) Differentiated ( RA) and undifferentiated ( RA) F9 cells 
were serum starved overnight and preincubated with 10 nM 
leptomycin B (LMB; final concentration) for 4 h, and then stimulated 
with 15% FBS for 90 min. Cells were lysed in SDS sample buffer 
separated on SDS–polyacrylamide (7.5%) gels, c-Fos expression 
and MAPK activation (pErk) was determined by immunoblotting, 
and  -actin was used as a control. (B and C) Differentiated
( RA) and undifferentiated ( RA) F9 cells were serum starved over-
night and incubated with 10 nM LMB for 30 min before and 10 
min during stimulation with 15% FBS as described in Adachi et al. (2000). Activated MAPK (B, phospho-Erk) or total MAPK (C, Erk) 
were detected by rhodamine red–conjugated secondary antibodies (red) and analyzed by immunofluorescence confocal microscopy. 
Nuclei were counterstained with TOTO-3 (green). 
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however, the transcription-dependent activity of MAPK in
the nucleus, which is required for mitogenesis, is suppressed.
The cytoplasmic MAPK activity is not suppressed upon dif-
ferentiation, allowing the differentiated endoderm cells to
respond to the Ras/MAPK signal that is unrelated to cell di-
vision (Fig. 9).
 
Regulation of nuclear translocation of MAPK
 
Nucleocytoplasmic localization of MAPK is a pivotal point
in regulation of its downstream targets, including those in-
volved in growth regulation, differentiation, and cell func-
tion. Nuclear accumulation of p42/p44 MAPK is observed
after mitogenic stimulation, which may persist for up to 6 h
(Volmat et al., 2001), and is believed to be accompanied by
neosynthesis of nuclear anchoring proteins. The nucleus has
been proposed to act as an “anchoring and inactivating cen-
ter,” restricting MAPK from activation by MEK in the cyto-
plasm (Volmat et al., 2001; Pouyssegur et al., 2002).
Although the mechanisms regulating nucleocytoplasmic
translocation of MAPK are fairly well described, our finding
in F9 EC and ES cells that differentiation restricts nuclear
access of activated MAPK is only the second physiological
example of this kind of regulation. Human diploid fibro-
blasts that have undergone replicative senescence, which is
characterized by a loss of proliferative capacity and impaired
expression of c-Fos and other immediate early genes in re-
sponse to mitogens and serum, show a reduced abundance
of nuclear activated MAPK (Tresini et al., 2001). The de-
 
creased nuclear abundance of active MAPK is accompanied
by decreased activation of Elk-1 and reduced c-Fos expres-
sion, but the senescent fibroblasts differ from the F9 and ES
cells in that total number of MAPK molecules is increased.
In the senescent fibroblasts, it was suggested that the abun-
dant unphosphorylated MAPK molecules compete for phos-
phorylated MAPK for dimerization and nuclear transloca-
tion, resulting in a reduced fraction of activated MAPK in
the nucleus (Tresini et al., 2001). In general, systems that
are aging affected, including primary rat hepatocytes in cul-
ture, mouse T lymphocytes and macrophages, human lym-
phocytes, melanocytes, and fibroblasts, also exhibit aging- or
senescent-associated changes in MAPK signaling (Tresini et
al., 2001). We did not observe a change in the total amount
of MAPK protein in RA-differentiated F9 and ES cells, but
rather a reduction of total MAPK located in the nucleus. In-
stead, we conclude that the reduced amount of activated
MAPK in differentiated F9 and ES cells is the result of an
actin- and microtubule-dependent inhibitory mechanism on
nuclear translocation of the activated MAPK imposed by the
cells after differentiation (Fig. 9). This restriction of MAPK
nuclear entry may be a general mechanism for suppression
of proliferation in cell differentiation, as we have begun to
observe the restriction of MAPK nuclear entry in other types
of differentiated cells in tissues and primary cultures (un-
published data).
 
Role of cytoskeleton in regulation of MAPK nuclear entry
 
The regulated coupling of MAPK activation and c-Fos ex-
pression may be related to morphological changes in the cy-
toskeleton that accompany endodermal differentiation of F9
cells (Kurki et al., 1989; Burdsal et al., 1994), such that de-
stabilization may reconfigure a situation similar to the undif-
ferentiated cells. Moreover, the data reported here indicate
that serum-induced MAPK activation and nuclear import in
F9 cells do not depend on the microtubule and microfila-
ment network and regulation of the cytoskeleton. Rather,
disruption of the cell cytoskeleton results in an enhanced
Figure 8. Cytoskeleton-disrupting agents elevate MAPK activation 
and c-Fos expression in F9 cells. (A) Undifferentiated F9 cells ( RA) 
and cells differentiated with RA for 4 d ( RA) were serum starved 
overnight and pretreated with 10  M nocodazole (Noc), colchicine 
(Colch), or cytochalasin D (CytD), and solvent control (Ctl) for 30 
min before stimulating with 15% serum for 90 min. Serum-containing 
medium also contained the inhibitors at the same concentration. 
Equal protein for each sample was separated on 7.5% PAGE gels, 
and c-Fos and activated MAPK (pErk) were determined by immuno-
blotting. In this blot, the membranes were incubated with a mixture 
of antibodies to c-Fos and pErk to determine both signals simul-
taneously. Shown is a representative experiment repeated in triplicate. 
(B) F9 cells, with or without RA treatment, with or without cyto-
chalasin D and/or MEK inhibitor U0126 (10  M), were first serum 
starved overnight, and then stimulated with serum for 90 min. The 
cells were harvested to analyze for c-Fos expression and MAPK 
activation (pErk) by Western blotting.
Figure 9. Model for regulation of nucleocytoplasmic MAPK activity 
in endoderm differentiation of ES and EC cells. MAPK is a down-
stream effector of the Ras pathway regulated by mitogen such as 
serum or growth factors. MAPK phosphorylates the cytoplasmic 
substrate p90 ribosomal S6 kinase (p90RSK) and the nuclear substrate 
Elk-1. The nuclear activity of MAPK is the transcription-dependent 
signal and is required for mitogen-stimulated cell proliferation. 
Endoderm differentiation of ES and EC cells results in cell cytoskeleton-
dependent enhanced activation but also restriction of MAPK nuclear 
entry and suppression of cell growth. 
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MAPK activation and c-Fos expression, and suppression of
c-Fos expression by RA-induced differentiation is prevented
without an organized cytoskeleton. The enhanced MAPK
activation by inhibition of protein synthesis and disruption
of cell cytoskeleton has been previously observed (Kyriakis et
al., 1994). We conclude that the restriction of MAPK acti-
vation and nuclear entry requires an intact actin and micro-
tubule cytoskeleton.
The mechanism for the uncoupling of MAPK activation
and c-Fos expression has been investigated. The reduction in
activated MAPK in the nucleus of the differentiated F9 or
ES cells is not due to higher nuclear export because leptomy-
cin B had no effect nor to an increased dephosphorylation in
the nucleus because active MAPK actually remains elevated
for a longer period than in control cells and appears to be
severalfold more abundant, especially in ES cells. It is not
known if a protein that actively binds MAPK is expressed in
ES and EC cells, although one such protein, PEA-15, which
has been found to retain MAPK in cytoplasm in neural cells
(Formstecher et al., 2001), was not found in F9 cells in-
duced by RA (unpublished data).
When F9 cells undergo differentiation, a striking pheno-
type is the rearrangement of cell cytoskeleton (Kurki et al.,
1989; Burdsal et al., 1994). We favor the idea that in differ-
entiated cells, MAPK is tethered to actin and/or microtubule
filaments themselves or associates with a protein complex
hinged on endocytic cargos traveling along an actin or mi-
crotubule track. The arrangement of the cytoskeleton or the
directional transport of endocytic cargos may restrict the ac-
cess of MAPK for nuclear entry, leading to suppression of its
nuclear transcriptional-dependent activity, thus growth sup-
pression (Fig. 9). RA may induce the expression of a set of
proteins such as adaptors and regulators to allow such orga-
nization. This mechanism may underlie the importance of
cell adhesion and the cytoskeleton structure in the regula-
tion of mitogenic signaling and cell proliferation.
 
Materials and methods
 
Materials
 
RA (all-trans-RA) was purchased from Sigma-Aldrich and stock solutions
were prepared in DMSO. Tissue culture supplies were obtained from Fisher
Scientific; DME and FBS were purchased from Mediatech; and the ECL Su-
per-Signal West Dura extended duration substrate immunodetection re-
agents came from Pierce Chemical Co. Antibodies were obtained from mul-
tiple sources: Dab2/p96 monoclonal, clathrin heavy chain monoclonal,
and Erk1 monoclonal (BD Biosciences); Elk-1 polyclonal, phospho-Elk-1
monoclonal, c-Fos polyclonal, and PEA-15 polyclonal (Santa Cruz Biotech-
nology, Inc.); phospho-Erk2/1 monoclonal and actin monoclonal (Sigma-
Aldrich); and Erk2/1 polyclonal, phospho-p90RSK (Ser 380) polyclonal,
phospho-p90RSK (Thr 359/Ser 363) polyclonal, and phospo-AKT (Ser 473)
polyclonal (Cell Signaling Technology). Cy2-, FITC-, and Texas red–conju-
gated donkey anti–rabbit and anti–mouse IgGs came from Jackson Immu-
noResearch Laboratories. SlowFade and ProLong antifade mounting media,
Alexa488-conjugated donkey anti–mouse IgG, rhodamine red–conjugated
goat anti–mouse IgG, DAPI, TOTO-3, and PI were purchased from Molecu-
lar Probes. All other chemicals and supplies were obtained from Fisher Sci-
entific or Sigma-Aldrich and were reagent grade or higher.
 
Cell culture
 
F9 mouse EC cells were purchased from the American Type Culture Col-
lection and cultured on gelatin-coated tissue culture plates in DME con-
taining 10% heat-inactivated FBS and 1
 
 
 
 antibiotic-antimycotic solution.
The plates were coated with an autoclaved 0.1% gelatin solution overnight
at 4
 
 
 
C and washed with PBS before use. All-trans-RA (referred to as RA)
was added from a 1-mM stock solution in DMSO to a final concentration
of 0.1 mM, generally, 24 h after plating. Control cultures received an equal
volume of DMSO vehicle, which was generally 
 
 
 
0.01% of the final cul-
ture volume. Mouse RW-4 ES cells were maintained on a layer of irradi-
ated murine embryonic fibroblasts or feeder layer in ES cell medium with
LIF (ESGRO; Chemicon; Robertson, 1987). For experiments, the cells were
trypsinized and plated on gelatinized tissue culture plates without feeder
cells for 2 d in ES cell medium containing LIF, and then trypsinized and
plated in the presence of 0.1 mM RA for 4 d.
 
Cell fractionation
 
F9 cells were cultured 4 d in the presence of RA or DMSO vehicle, and
then incubated overnight (18–24 h) in DME containing 0.1% FBS and anti-
biotics/antimycotics (serum-depleted medium). For serum-stimulation ex-
periments, serum-depleted medium was removed and replaced with 15–
20% FBS-containing medium for various times (0–90 min) at 37
 
 
 
C, 5%
CO
 
2
 
. At the end of the treatment, cells were washed three times with ice-
cold PBS containing 0.5 mM sodium orthovanadate, scraped into hypo-
tonic lysis buffer (10 mM Tris, pH 7.4, 10 mM NaCl, 3 mM MgCl
 
2
 
, 1 mM
EGTA, 1 mM sodium orthovanadate, 10 mM NaF, and a protease inhibitor
cocktail; Sigma-Aldrich), and incubated on ice for 10 min (Fazioli et al.,
1993). The lysate was Dounce homogenized (40 strokes) with a tight-fit-
ting pestle and designated the total homogenate. To obtain the nuclear
fraction, the homogenate was centrifuged at 375 
 
g
 
 for 5 min, and the pellet
(nuclear fraction) was washed five times with hypotonic lysis buffer con-
taining 0.1% NP-40 to remove membrane and cytosolic contamination
and resuspended in lysis buffer containing 0.5% sodium deoxycholate,
0.1% SDS, and 0.2% NP-40. The soluble fraction was centrifuged twice at
375 
 
g
 
 to remove nuclear contamination and was designated the cytosolic
fraction. Fractions were centrifuged at 12,000 
 
g
 
 to remove insoluble mate-
rial. All procedures were performed on ice. Protein was quantitated using
DCC assay (Bio-Rad Laboratories) according to the manufacturer’s instruc-
tions. Immunoblotting was performed according to standard procedures,
as described previously (Smith et al., 2001b).
 
Immunofluorescence microscopy
 
F9 cells were first differentiated with RA and reseeded at 10
 
4
 
 cells/well
onto gelatin-coated Permanox 4-well slide chambers (Lab-Tek). For some
experiments, cells were seeded directly onto and differentiated in the slide
chambers. To process for immunocytochemistry, after treatment, cells
were washed two times with PBS and fixed and lysed in ice-cold methanol
at 
 
 
 
20
 
 
 
C for 5 min (Edwards et al., 1988), washed two times in PBS, and
blocked in PBS containing 3% BSA for 1 h at RT. The primary antibody
was diluted (1:200) into 3% BSA in PBS containing 0.1% Tween-20 and
incubated with the slides for 1 h at 37
 
 
 
C in a humidified chamber (Osborn
and Weber, 1982). The slides were washed three times with PBS contain-
ing 1% BSA and 0.1% Tween-20 and incubated with the appropriate sec-
ondary antibody (1:100–1:200) in 3% BSA at 37
 
 
 
C for 1 h. Slides were
washed four times with PBS, stained with PI (1:3,000 dilution of a 10-mg/
ml stock in water) for 2 min at RT, and washed three more times with PBS.
The slides were mounted in SlowFade or ProLong media according to the
manufacturer’s directions. Cells were viewed on a laser scanning confocal
microscope (model 200; Bio-Rad Laboratories) using a 60
 
 
 
 water objec-
tive, and images were deconvoluted using the Laser Sharp software (Bio-
Rad Laboratories) and analyzed using Adobe Photoshop.
To determine the effect of leptomycin B on MAPK and phospho-MAPK
localization, serum-starved cells were incubated with 10 nM leptomycin B
for 30 min in serum-free medium and stimulated with 15% FBS for 10 min
in the continued presence of leptomycin B. Cells were processed for im-
munocytochemistry as described in the previous paragraph. Antibody con-
trols (minus the primary antibody) demonstrated little to no fluorescence
staining, indicating the specificity of the antibodies. The Erk1 mAb (BD
Biosciences) was used at 1:50 dilution, and the secondary antibody,
rhodamine red–conjugated goat anti–mouse IgG (Molecular Probes), was
used at 1:300. Cell nuclei were counterstained with TOTO-3 diluted
1:10,000 in PBS for 2 min at RT.
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